Serum thyroglobulin is associated with orbitopathy in Graves' disease
| Autor: | P. Emadi, Ö. Ljunggren, Martin Lundqvist, F. A. Karlsson, Kristina E. Almby, S. Khamisi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Endocrinology Diabetes and Metabolism medicine.medical_treatment Graves' disease Disease Gastroenterology Iodine Radioisotopes Graves' orbitopathy 0302 clinical medicine Endocrinology Graves’ ophthalmopathy biology Middle Aged Prognosis Graves Disease 030220 oncology & carcinogenesis Endokrinologi och diabetes Original Article Female Antibody Orbit Adult Thyroid Hormones medicine.medical_specialty 030209 endocrinology & metabolism Trab Endocrinology and Diabetes Thyroglobulin Graves' ophthalmopathy 03 medical and health sciences Pharmacotherapy Antithyroid Agents Thyroid peroxidase Internal medicine Tobacco Smoking medicine Humans Aged Rheumatology and Autoimmunity Reumatologi och inflammation Methimazole business.industry Graves’ orbitopathy medicine.disease Graves Ophthalmopathy Thyroxine biology.protein Graves’ disease business Biomarkers |
| Zdroj: | Journal of Endocrinological Investigation |
| Popis: | Purpose Serum thyroglobulin levels are often elevated in Graves’ disease (GD) and in most cases decrease during treatment. Its relation to Graves’ orbitopathy (GO) has not been clarified. Previously, a risk of GO has been linked to smoking, TSH receptor stimulation, high TSH-receptor antibodies (TRAb), low thyroid peroxidase and thyroglobulin antibodies (TPOAb, TgAb). Methods We examined Tg levels in 30 consecutive patients with GD were given drug therapy (methimazole + thyroxine) for up to 24 months. GO was identified by clinical signs and symptoms. 17 patients had GO, 11 of whom had it at diagnosis while 6 developed GO during treatment. During the study, 5 subjects were referred to radioiodine treatment, 3 to surgery. The remaining 22 subjects (GO n = 12, non-GO n = 10) completed the drug regimen. Results At diagnosis, Tg levels in GO patients (n = 11) were higher (84, 30–555 µg/L, median, range) than in non-GO patients (n = 19) (38, 3.5–287 µg/L), p = 0.042. Adding the 6 subjects who developed eye symptoms during treatment to the GO group (n = 17), yielded p = 0.001 vs. non-GO (n = 13). TRAb tended to be higher, while TPOAb and TgAb tended to be lower in the GO group. For the 22 patients who completed the drug regimen, Tg levels were higher in GO (n = 12) vs. non-GO (n = 10), p = 0.004, whereas TRAb levels did not differ. Conclusion The data may suggest that evaluation of thyroglobulin levels in GD could contribute to identify patients at increased risk of developing GO. Possibly, thyroidal release of Tg in GD reflects a disturbance that also impacts retroorbital tissues. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|